比较西妥昔单抗与顺铂联合放疗对晚期头颈癌患者营养影响的随机研究
本研究基于ARTSCAN III研究,纳入80例晚期头颈癌患者,随机接受西妥昔单抗(38例)或顺铂(42例)联合放疗,比较治疗开始后3个月体重下降。结果显示两组3个月体重下降无显著差异,但西妥昔单抗组治疗结束时体重下降更少、肠内喂养管使用更少、躯体功能更好,而治疗开始后3个月疼痛相关问题更多;6个月和12个月时两组无差异。营养不良患病率在各时间点均无显著差异。
要点
- 西妥昔单抗组与顺铂组治疗开始后3个月体重下降无显著差异。
- 西妥昔单抗组治疗结束时体重下降更少、肠内喂养管更少、躯体功能更好,但治疗开始后3个月疼痛相关问题更多。
- 两组在6个月和12个月时无差异,营养不良患病率各时间点均无显著差异。
核心结论
- 本研究未能支持西妥昔单抗联合放疗较顺铂在营养不良患病率方面具有假设的获益。
研究设计与样本
- 随机研究,基于ARTSCAN III研究纳入80例晚期头颈癌患者,随机接受西妥昔单抗(38例)或顺铂(42例)联合放疗。
- 在诊断时及治疗开始后6周、3个月、6个月和12个月评估体重、体成分、肠内喂养管依赖及选定的生活质量评分(EORTC QLQ-C30和QLQ-H&N35)。
主要发现
- 两组治疗开始后3个月体重下降无显著差异。
- 西妥昔单抗组治疗结束时体重下降显著更少、肠内喂养管使用更少、躯体功能更好,但治疗开始后3个月疼痛相关问题更多。
- 两组在6个月和12个月时无差异。
- 营养不良患病率在各时间点均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck cancer (HNC) patients have a high risk of developing malnutrition. This randomized study aimed to compare the effect of weekly cisplatin or cetuximab combined with radiotherapy on weight loss at 3 months after treatment was started. Secondary outcomes were the prevalence of malnutrition using the Global Leadership Initiative on Malnutrition (GLIM) criteria, feeding tube dependence and health related quality of life from a nutritional perspective. METHODS: Patients from the ARTSCAN III study with advanced HNC were assessed for weight, body composition, enteral tube dependence and selected quality-of-life scores (EORTC QLQ-C30 and QLQ-H&N35) at diagnosis and 6 weeks 3, 6 and 12 months after treatment initiation. RESULTS: Of the 80 patients, 38 and 42 were randomized to receive cetuximab and cisplatin treatment, respectively. There was no significant difference in weight loss at 3 months between the two study groups. However, the cetuximab group had significantly less weight loss, fewer enteral feeding tubes and better physical functioning at the end of treatment but more pain-related problems 3 months after treatment initiation. No differences between the groups were found at 6 and 12 months. The prevalence of malnutrition was not significantly different at any time point. CONCLUSION: The hypothesized benefit of concomitant treatment with cetuximab over cisplatin regarding the prevalence of malnutrition was not supported by this study.
引用
- Berg M, Hansson C, Silander E, et al. A randomized study comparing the nutritional effects of radiotherapy with cetuximab versus cisplatin in patients with advanced head and neck cancer. Head Neck. 2024. PMID: 38192119. doi:10.1002/hed.27619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。